Emergent Initiates Phase 2 Study of TRU-016 in Combination with Bendamustine in Patients with Relapsed Chronic Lymphocytic Leukemia

ROCKVILLE, Md.--(BUSINESS WIRE)--Dec. 28, 2011-- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 2 study (protocol 16201) of TRU-016 in combination with bendamustine for patients with relapsed chronic lymphocytic leukemia (CLL). The initiation of this clinical trial triggers a $6 million milestone payment to Emergent. TRU-016 is a humanized anti-CD37 mono-specific protein therapeutic in development for the treatment of B-cell malignancies. “Preclinical studies have demonstrated increased anti-tumor activity for the combination of bendamustine and TRU-016 beyond the results achieved ...